[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648353":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":12,"collaborators":16,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":24,"acronym":25,"eligibilityCriteria":26,"healthyVolunteers":22,"sex":27,"minAge":28,"maxAge":10,"enrollmentInfo":29,"targetDuration":32,"studyType":33,"phases":10,"briefSummary":34,"conditions":35,"keywords":37,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Centre for Chronic Disease Control, India","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Adults with Cardiovascular-Kidney-Metabolic Syndrome (CKMS)",null,"Adults aged 18 years or older with Cardiovascular-Kidney-Metabolic Syndrome (CKMS) or CKMS-related risk factors who meet the study eligibility criteria and provide informed consent. Participants will receive routine clinical care and will be prospectively observed to assess CKMS staging, clinical characteristics, risk factors, prescription practices, quality of life, and disease progression over time. No study-specific intervention will be assigned.",{"type":13,"investigatorFullName":14,"investigatorTitle":15,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Dr. Dorairaj Prabhakaran","Executive Director",[17],{"name":18,"class":19},"Sun Pharmaceutical Industries Limited","INDUSTRY","100648353","cardiovascular-kidney-metabolic-syndrome-registry-100648353",false,"NCT07718789","Cardiovascular-Kidney-Metabolic Syndrome Registry","CKMS Registry","Inclusion Criteria:\n\n1. Adults ≥18 years visiting select tertiary care hospitals AND\n2. Presenting with signs and\u002For symptoms of CKMS :\n\n   2.1. Adiposity i.e., Body Mass Index \\> 23, and\u002For large waist circumference \\[women: ≥ 80 cm; men: ≥ 90 cm\\] AND\u002FOR 2.2. Metabolic syndrome i.e., new or a known case of hypertension, type-2 diabetes, dyslipidaemia, chronic kidney disease, and\u002For PCOS.\n\n   AND\u002FOR 2.3. Presenting with signs of subclinical CVD and\u002For with a history of clinical CVD with metabolic syndrome AND\n3. Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n1. Stage 0 CKMS i.e., a healthy state characterized by normal body weight, absence of metabolic risk factors such as hypertension, type-2 diabetes, dyslipidemias, preserved kidney function with no evidence of CKD, and no subclinical or clinical manifestations of CVDs.\n2. Neuro-cognitive, psychiatric, or any surgical conditions which prevents in obtaining reliable clinical data.\n3. Any surgical and\u002For medical condition that is likely to prevent the participant from complying with the requirements of the study or completing the study.\n4. Participants already taking part in another clinical trial.\n5. Pregnant and\u002For lactating women.","ALL","18 Years",{"count":30,"type":31},2250,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this observational registry study is to learn about cardiovascular-kidney-metabolic syndrome, also called CKMS, among adults receiving care at tertiary care hospitals in India. CKMS describes the close relationship between excess body weight, metabolic conditions such as high blood pressure and diabetes, kidney disease, and cardiovascular disease.\n\nThe main questions this study aims to answer are:\n\n* What proportion of participants are in each stage of CKMS when they enter the study?\n* How do participants' CKMS stage and related health factors change over 12 months?\n* How does participants' quality of life change over time?\n* What are the prescription practices for CKMS?\n\nParticipants will:\n\n* Provide information about their general health, medical history, lifestyle, current medicines, family history, and quality of life.\n* Have measurements taken, including height, weight, waist circumference, and blood pressure.\n* Provide blood and urine samples for tests related to blood sugar, cholesterol, kidney function, inflammation, and heart health.\n* Undergo an electrocardiogram, also called an ECG, and a coronary artery calcium scan according to the study schedule.\n* Return for follow-up visits at 6 months and 12 months after joining the study. Participants will continue to receive their usual medical care as decided by their treating doctor. No experimental medicine or treatment will be provided as part of this study.\n\nThis multi-centre registry will include approximately 2250 adults from five tertiary care hospitals in India. The information collected will help researchers understand the burden, progression, risk factors, quality of life, and treatment patterns of CKMS in India.",[36],"Cardiovascular Kidney Metabolic Syndrome",[38,39,40,41,42,43,44,45,46,47],"Cardiovascular-Kidney-Metabolic Syndrome (CKMS)","Cardiovascular Disease","Cardiometabolic Health","Chronic Kidney Disease","Type 2 Diabetes Mellitus","Hypertension","Hyperglyceridaemia","Obesity","CKMS Staging","Registry","NOT_YET_RECRUITING","2026-07-16",{"date":51,"type":52},"2026-07-22","ACTUAL",{"date":54,"type":31},"2026-07-24",{"date":56,"type":31},"2027-12-31",{"name":5,"class":6}]